Related Experiment Video
Updated: Apr 28, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Nanoparticle ligand presentation for targeting solid tumors
1Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa, 52242, USA.
Abstract:
Among the many scientific advances to come from the study of nanoscience, the development of ligand-targeted nanoparticles to eliminate solid tumors is predicted to have a major impact on human health. There are many reports describing novel designs and testing of targeted nanoparticles to treat cancer. While the principles of the technology are well demonstrated in controlled lab experiments, there are still many hurdles to overcome for the science to mature into truly efficacious targeted nanoparticles that join the arsenal of agents currently used to treat cancer in humans. One of these hurdles is overcoming unwanted biodistribution to the liver while maximizing delivery to the tumor. This almost certainly requires advances in both nanoparticle stealth technology and targeting. Currently, it continues to be a challenge to control the loading of ligands onto polyethylene glycol (PEG) to achieve maximal targeting. Nanoparticle cellular uptake and subcellular targeting of genes and siRNA also remain a challenge. This review examines the types of ligands that have been most often used to target nanoparticles to solid tumors. As the science matures over the coming decade, careful control over ligand presentation on nanoparticles of precise size, shape, and charge will likely play a major role in achieving success.
Insights
Ligand-targeted nanoparticles show promise for cancer treatment, but challenges remain in optimizing delivery to tumors and avoiding the liver. Future success depends on precise control over nanoparticle properties and ligand presentation.
Area of Science:
- Nanoscience and Nanotechnology
- Biomedical Engineering
- Oncology
Background:
- Ligand-targeted nanoparticles are a promising strategy for cancer therapy.
- Current research focuses on overcoming challenges in nanoparticle design and delivery for solid tumors.
Purpose of the Study:
- To review ligands used for targeting nanoparticles to solid tumors.
- To highlight hurdles in nanoparticle development for clinical cancer treatment.
Main Methods:
- Review of scientific literature on ligand-targeted nanoparticles for cancer.
- Analysis of challenges in nanoparticle biodistribution, ligand loading, and cellular uptake.
Main Results:
- Significant hurdles exist in translating nanoparticle technology from lab to clinic.
- Optimizing nanoparticle stealth and targeting is crucial for effective tumor delivery.
- Controlling ligand density on nanoparticles (e.g., on polyethylene glycol) remains a challenge.
Conclusions:
- Precise control over nanoparticle size, shape, charge, and ligand presentation is essential for successful cancer therapy.
- Advances in nanoparticle stealth and targeting are needed to improve efficacy and minimize off-target effects.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against...

